Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Company Info
SIC2836
Composite FIGIBBG011RT3R55
CIK0001894562
IPOOct 20, 2022
Sectorbiological products, (no diagnostic substances)
The chart shows the growth of an initial investment of $10,000 in Prime Medicine, Inc. Common Stock, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Prime Medicine, Inc. Common Stock (PRME) has returned -5.14% so far this year and 138.85% over the past 12 months. Looking at the last ten years, PRME has achieved an annualized return of -16.66%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
PRME
1M-16.58%
6M-49.85%
YTD-5.14%
1Y138.85%
5Y-29.43%
10Y-16.66%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Prime Medicine, Inc. Common Stock (PRME) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
8.86%
23.20%
-20.91%
-6.48%
2025
-4.44%
-6.67%
-23.17%
-12.18%
-32.95%
109.32%
53.91%
-7.69%
74.76%
-10.67%
-22.67%
-6.22%
2024
-28.09%
34.01%
-19.63%
-30.21%
32.79%
-22.24%
10.00%
-23.84%
-12.05%
-0.77%
-15.64%
-12.84%
2023
-6.04%
-5.79%
-25.54%
11.23%
-0.36%
6.16%
3.57%
-10.96%
-28.43%
-31.76%
11.69%
21.20%
2022
-0.79%
-9.19%
7.03%
2019
13.03%
1.30%
3.52%
-0.46%
-2.00%
0.32%
-0.05%
0.70%
-2.53%
2018
0.96%
-5.08%
4.56%
0.61%
0.71%
1.46%
-0.18%
6.24%
-3.66%
-6.09%
2.94%
-8.54%
2017
0.31%
1.09%
-0.67%
2.59%
0.67%
0.35%
0.90%
-1.13%
-0.60%
1.82%
2.44%
-3.16%
2016
0.63%
-1.38%
0.44%
4.07%
-1.98%
-2.13%
1.88%
-2.50%
0.89%
Performance Indicators
The charts below present risk-adjusted performance metrics for Prime Medicine, Inc. Common Stock (PRME) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of PRME compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Prime Medicine, Inc. Common Stock volatility is 4.09%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
Liabilities And Equity (USD)
342.73M
297.51M
193.85M
360.31M
Equity Attributable To Parent (USD)
120.87M
153.15M
133.07M
316.27M
Equity Attributable To Noncontrolling Interest (USD)
The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.
Benzinga•Usa News Group
AI Insight
Developing next-generation prime editing technology that reduces off-target risks and promises more precise manufacturing of gene-corrected cells at scale, addressing a key market challenge.
Prime Medicine announced that company management will participate in three upcoming healthcare and biotech conferences in March 2026, including fireside chats at the TD Cowen Health Care Conference and Citizens Life Sciences Conference, as well as 1x1 meetings at the Jefferies Biotech on the Beach Summit. Live webcasts of the fireside chats will be available on the company's website.
GlobeNewswire Inc.•Prime Medicine, Inc.
AI Insight
The announcement is routine corporate communication regarding conference participation. While it demonstrates active investor engagement and continued advancement of their Prime Editing platform across multiple therapeutic areas, the news itself is procedural in nature without material updates on clinical progress, regulatory milestones, or financial performance.
The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.
Benzinga•Prnewswire
AI Insight
Published first-in-human Phase 1/2 data in New England Journal of Medicine for PM359 treating chronic granulomatous disease, demonstrating safety and efficacy of Prime Editing technology. Both patients exceeded clinical benefit threshold with no clinically significant adverse events.
Prime Medicine published Phase 1/2 clinical data for PM359, an investigational gene therapy for chronic granulomatous disease, demonstrating safety and early clinical efficacy in two patients with promising results in neutrophil restoration and disease symptom improvement.
GlobeNewswire Inc.•Prime Medicine, Inc.
AI Insight
Reported successful first-in-human clinical trial results with positive patient outcomes, demonstrated safety of their prime editing technology, and showed potential for treating genetic diseases
Prime Medicine reported Q3 2025 financial results, highlighting progress in genetic therapies for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file IND/CTA applications in 2026-2027 and new preclinical data to be presented at AASLD.
GlobeNewswire Inc.•Prime Medicine, Inc.
AI Insight
Company showed progress in pipeline development, nominated new development candidates, strengthened leadership, maintained financial runway into 2027, and presented promising preclinical data
Prime Medicine reported Q2 2025 earnings with a net loss of $52.6 million, below analyst estimates. The company demonstrated clinical proof-of-concept for Prime Editing in chronic granulomatous disease and extended its cash runway into 2027 through strategic restructuring and funding.
The Motley Fool•Jesterai
AI Insight
Mixed financial performance with reduced net loss, successful clinical proof-of-concept, secured additional funding, but still reporting operating losses and below analyst revenue expectations
Prime Medicine is conducting a public offering of 38 million shares at $3.30 per share, expecting to raise approximately $125.4 million. The Cystic Fibrosis Foundation will purchase 1,818,181 shares, and the offering is expected to close on August 1, 2025.
GlobeNewswire Inc.•Gregory Dearborn
AI Insight
The company is raising significant capital through a public stock offering, indicating growth potential and investor interest in their gene editing technology
Prime Medicine, a clinical-stage biotech company, announced a new preclinical program targeting alpha-1 antitrypsin deficiency, a genetic disorder affecting lung and liver function. Investors reacted positively to the company's plans to file an Investigational New Drug Application by mid-2026, but the development risks associated with clinical-stage biotechs remain.
The Motley Fool•Johnny Rice
AI Insight
The company announced a promising new preclinical program targeting a serious genetic disorder, which generated positive investor reaction and a stock price surge.
Prime Medicine announced a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder. The program leverages Prime Medicine's proprietary Prime Editing technology and is expected to file an IND/CTA in mid-2026.
GlobeNewswire Inc.•
AI Insight
The article highlights Prime Medicine's progress in developing a preclinical program for AATD using its Prime Editing technology, which has shown promising results in restoring the disease-causing mutation. The company expects to file an IND/CTA in mid-2026, indicating advancement of the program.
Prime Medicine reported progress in its Wilson's Disease program, including in vivo data demonstrating efficient correction of disease-causing mutations. The company also announced a strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies and expects to report initial data from its Phase 1/2 trial of PM359 for p47phox CGD in 2025.
GlobeNewswire Inc.•Prime Medicine, Inc.
AI Insight
The article highlights several positive developments for Prime Medicine, including progress in its Wilson's Disease program, a strategic collaboration with Bristol Myers Squibb, and the expected initiation of a Phase 1/2 trial for its PM359 program.
